In conclusion, by carefully interrogating drug response at the systems level, we uncovered that through the direct targeting of RUNX1 itself and RAS family signaling a key mechanism of resistance to targeted therapy in FLT3-ITD AML can be overcome. This evidence concerns the gene RUNX1 and acute myeloid leukemia.